Flag of the European Union EU Clinical Trials Register Help

Clinical trials for ACT

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44351   clinical trials with a EudraCT protocol, of which   7378   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    421 result(s) found for: ACT. Displaying page 12 of 22.
    «« First « Previous 8  9  10  11  12  13  14  15  16  Next» Last»»
    EudraCT Number: 2021-005752-10 Sponsor Protocol Number: AT-100/001 Start Date*: 2023-04-20
    Sponsor Name:Airway Therapeutics, Inc.
    Full Title: A Phase 1b, Randomized, Blinded, Dose-Determined Study Evaluating the Safety and Tolerability Profile of Intervention with AT-100 (rhSP-D) in Preterm Neonates at High Risk for the Development of Br...
    Medical condition: Bronchopulmonary Dysplasia (BPD)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10006475 Bronchopulmonary dysplasia PT
    Population Age: Preterm newborn infants, Under 18 Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-003975-36 Sponsor Protocol Number: 9766-CL-0107 Start Date*: 2019-12-13
    Sponsor Name:Astellas Pharma Global Development, Inc.
    Full Title: A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillos...
    Medical condition: Invasive Aspergillosis and Invasive Mucormycosis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10062642 Invasive mycosis LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) DE (Completed) ES (Ongoing) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2021-003608-41 Sponsor Protocol Number: RD.06.SPR.204245 Start Date*: 2022-01-12
    Sponsor Name:Galderma S.A.
    Full Title: Evaluation of acne-induced hyperpigmentation during treatment of acne vulgaris subjects with trifarotene 50 µg/g cream versus vehicle cream over 24 weeks.
    Medical condition: Moderate acne vulgaris with acne-induced post-inflammatory hyperpigmentation (PIH)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10000519 Acne vulgaris LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2019-004309-28 Sponsor Protocol Number: MEU19/383 Start Date*: 2020-03-04
    Sponsor Name:The Medicines Evaluation Unit (MEU) Ltd. (Investigator led study)
    Full Title: Application of Chronotherapy to Asthma: Towards the Personalisation of Asthma Management. A randomised, mechanistic study of 400mcg Clenil® Modulite® (Beclometasone dipropionate) in the morning ...
    Medical condition: Mild to moderate atopic asthma
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004855 10001705 Allergic asthma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2016-001263-37 Sponsor Protocol Number: AGO/2016/003 Start Date*: 2016-06-23
    Sponsor Name:UZ Gent
    Full Title: Phase I trial of stereotactic body radiotherapy with concurrent pembrolizumab in metastatic urothelial cancer.
    Medical condition: Metastatic urothelial cancer
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2013-003191-12 Sponsor Protocol Number: TUD-2DAUNO-058 Start Date*: 2014-01-31
    Sponsor Name:Technische Universität Dresden
    Full Title: Randomized comparison between two dose levels of daunorubicin and between one versus two cycles of in-duction therapy for adult patients with acute myeloid leukemia ≤65 years
    Medical condition: Newly diagnosed AML other than acute promyelocytic leukemia (APL) according to WHO criteria, i.e. bone marrow aspirate or biopsy must contain ≥20% blasts of all nucleated cells or differential bloo...
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10000886 Acute myeloid leukemia LLT
    21.1 100000004864 10066353 Treatment related acute myeloid leukemia LLT
    21.0 100000004864 10000887 Acute myeloid leukemia in remission LLT
    21.0 100000004864 10054294 Acute myeloid leukemia (in remission) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2019-004883-23 Sponsor Protocol Number: APHP191116 Start Date*: 2020-10-06
    Sponsor Name:APHP
    Full Title: A phase I/II Study evaluating the safety and the efficacy of Human T Lymphoid Progenitor (HTLP) injection to accelerate immune reconstitution after umbilical cord blood (UCB) transplantation in adu...
    Medical condition: Adult patients (n=10) requiring an allogeneic HSCT for the treatment of AML with an unfavorable prognosis according to international criteria in first complete remission or second complete remissio...
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000881 Acute myeloid leukaemia (in remission) PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-000729-35 Sponsor Protocol Number: PRODIGE33-BALLAD Start Date*: 2015-06-16
    Sponsor Name:Centre Hospitalier Universitaire (CHU) de Dijon
    Full Title: BALLAD - A TRIAL TO EVALUATE THE POTENTIAL BENEFIT OF ADJUVANT CHEMOTHERAPY FOR SMALL BOWEL ADENOCARCINOMA
    Medical condition: SMALL BOWEL ADENOCARCINOMA
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-001449-11 Sponsor Protocol Number: CLI-01535AA0-02 Start Date*: 2021-11-09
    Sponsor Name:CHIESI FARMACEUTICI S.P.A.
    Full Title: An exploratory, double-blind, randomised, multicenter, psychopharmacological study in adult patients with moderate to severe asthma to compare two pressurised Metered-Dose Inhalers (pMDIs) on patie...
    Medical condition: Moderate to severe asthma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-002831-65 Sponsor Protocol Number: 21121214 Start Date*: 2018-12-18
    Sponsor Name:Belgian Group of Digestive Oncology (BGDO)
    Full Title: BALLAD BELGIUM: A trial to evaluate the potential benefit of adjuvant chemotherapy for small bowel adenocarcinoma "THE BELGIAN COMPONENT OF THE GLOBAL BALLAD POOLED DATA ANALYSIS"
    Medical condition: small bowel adenocarcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2023-000138-13 Sponsor Protocol Number: CITATION Start Date*: 2023-04-05
    Sponsor Name:ISTITUTO NAZIONALE TUMORI - IRCCS FONDAZIONE PASCALE
    Full Title: Neo-adjuvant Chemo and immunotherapy with durvalumab (MEDI4736) and tremelimumab (MEDI1123) In The pre-operAtive Treatment of locally advanced cholangIOcarciNoma: an exploratory and translational s...
    Medical condition: Locally advanced cholangiocarcinoma patients
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008593 Cholangiocarcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-005889-17 Sponsor Protocol Number: WATOS-PE Start Date*: 2023-05-22
    Sponsor Name:Fundació Institut d'Investigació i Innovació Parc Taulí (I3PT)
    Full Title: PAIN CONTROL WITH THE USE OF WALANT IN TOTAL TRAPEZECTOMY. RANDOMIZED CLINICAL TRIAL
    Medical condition: Thumb trapeziometacarpal joint osteoarthritis treated by total trapeziectomy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-004870-22 Sponsor Protocol Number: AMB-051-02 Start Date*: 2021-02-24
    Sponsor Name:AmMax Bio., Inc.
    Full Title: A Phase 2, Adaptive, Open-Label, Multiple-Dose, Dose-Escalation Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Intravenous AMB-05X in Subjects with Tenosynovial Giant...
    Medical condition: Tenosynovial Giant Cell Tumor
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10018253 Giant cell tumor of tendon sheath LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) PL (Completed) NL (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2011-000607-41 Sponsor Protocol Number: MMC-BCG-1 Start Date*: 2011-03-04
    Sponsor Name:Centre Hospitalier de Jolimont-Lobbes-Tubize-Nivelles
    Full Title: A phase I/II multicentric Belgian prospective novel sequential chemo-immunotherapy regimen for adjuvant treatment in non-muscle invasive bladder cancer.
    Medical condition: Patients with intermediate/high risk non-muscle invasive bladder cancer (NMIBC) • intermediate risk tumours – Ta, T1 Grade 1, Grade 2, multifocal and tumours larger than 3 cm • high risk tumours – ...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005003 Bladder cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-000844-31 Sponsor Protocol Number: VBP15-BMD-001 Start Date*: 2023-05-18
    Sponsor Name:ReveraGen BioPharma Inc.
    Full Title: A Phase II Pilot Trial of Vamorolone vs. Placebo for the Treatment of Becker Muscular Dystrophy
    Medical condition: Becker Muscular Dystrophy
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-003561-15 Sponsor Protocol Number: MYSTEP1 Start Date*: 2016-08-30
    Sponsor Name:University Hospital of Tuebingen
    Full Title: Safety and Tolerance of Immunomodulating Therapy with Donor-specific Mesenchymal Stem Cells in Pediatric Living-Donor Liver Transplantation
    Medical condition: Side effects of life-long immunosuppressive medication account for major morbidity after pediatric liver transplantation and impair quality of life. In-vivo and in-vitro studies have shown that MSC...
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004865 10024716 Liver transplantation LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-000242-35 Sponsor Protocol Number: 18CT0003 Start Date*: Information not available in EudraCT
    Sponsor Name:E-Pharma Trento SpA
    Full Title: Randomized, double blind, double dummy, parallel-groups, clinical trial on efficacy and safety of ibuprofen/N-acetylcysteine fixed dose combination vs. individual components (ibuprofen and N-acetyl...
    Medical condition: symptomatic non-complicated upper respiratory tract infections
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10046309 Upper respiratory tract infections HLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2025-000122-33 Sponsor Protocol Number: 5354-CL-0301 Start Date*: 2025-04-16
    Sponsor Name:Astellas Pharma Global Development Inc.
    Full Title: A Phase 3, Multicenter, Prospective, Randomized, Open label Study for Intraoperative Ureter(s) Visualization When Using ASP5354 with Near infrared Fluorescence (NIR-F) Imaging in Participants Under...
    Medical condition: visualisation of ureter
    Disease: Version SOC Term Classification Code Term Level
    27.0 10022891 - Investigations 10068979 Imaging procedure PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2021-001648-91 Sponsor Protocol Number: TRIPLEX Start Date*: 2021-09-21
    Sponsor Name:Norwegian University of Science and Technology
    Full Title: Randomized phase III trial investigating the survival benefit of adding thoracic radiotherapy to durvalumab (MEDI4736) immunotherapy plus chemotherapy in extensive stage small-cell lung cancer
    Medical condition: Extensive stage small-cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041068 Small cell lung cancer extensive stage PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Trial now transitioned) EE (Trial now transitioned) NL (Trial now transitioned) IS (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-001653-99 Sponsor Protocol Number: I6T-MC-AMBI Start Date*: 2021-01-15
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 3b, Randomized, Double-Blind, Parallel-Arm, Placebo- and Active- Controlled Treat-Through Study of Mirikizumab and Vedolizumab in Participants with Moderately to Severely Active Ulcerativ...
    Medical condition: Moderately to Severely Active Ulcerative Colitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10045365 Ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) LT (Prematurely Ended) DE (Prematurely Ended) FR (Completed) LV (Prematurely Ended) AT (Prematurely Ended) BE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 8  9  10  11  12  13  14  15  16  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Jul 25 05:18:38 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA